Accéder au contenu
Merck

MAB8257B

Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated

clone A1, Chemicon®, from mouse

Slide 1 of 1
Se connecter pour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Sélectionner une taille de conditionnement

100 μG

518,00 €

518,00 €

Date d'expédition estimée le11 décembre 2025Détails

Demander une commande groupée

A propos de cet article

Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41

Principaux documents

Voir toute la documentation

Passer à

Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Source biologique

mouse

Niveau de qualité

300

Conjugué

biotin conjugate

Forme d'anticorps

purified immunoglobulin

Type de produit anticorps

primary antibodies

Clone

A1, monoclonal

Espèces réactives

human

Fabricant/nom de marque

Chemicon®

Technique(s)

immunofluorescence: suitable

Isotype

IgG2a

Conditions d'expédition

wet ice

Comparer avec des articles similaires

Voir la comparaison complète

Montrer les différences

1 of 4

Cet article
MAB8257MAB8257FMAB8671B
Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated clone A1, Chemicon®, from mouse

Sigma-Aldrich

MAB8257B

Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated

Anti-Influenza A Antibody, nucleoprotein, clone A1 clone A1, Chemicon®, from mouse

Sigma-Aldrich

MAB8257

Anti-Influenza A Antibody, nucleoprotein, clone A1

Anti-Influenza A Antibody, nucleoprotein, clone A1, FITC-conjugated clone A1, Chemicon®, from mouse

Sigma-Aldrich

MAB8257F

Anti-Influenza A Antibody, nucleoprotein, clone A1, FITC-conjugated

Anti-Influenza B Antibody, Core, clone 22D5-12-13, biotin-conjugated clone 22D5-12-13, Chemicon®, from mouse

Sigma-Aldrich

MAB8671B

Anti-Influenza B Antibody, Core, clone 22D5-12-13, biotin-conjugated

biological source

mouse

biological source

mouse

biological source

mouse

biological source

mouse

antibody form

purified immunoglobulin

antibody form

purified immunoglobulin

antibody form

purified antibody

antibody form

purified immunoglobulin

clone

A1, monoclonal

clone

A1, monoclonal

clone

A1, monoclonal

clone

22D5-12-13, monoclonal

species reactivity

human

species reactivity

human

species reactivity

human

species reactivity

human

conjugate

biotin conjugate

conjugate

-

conjugate

FITC conjugate

conjugate

biotin conjugate

technique(s)

immunofluorescence: suitable

technique(s)

immunofluorescence: suitable

technique(s)

immunofluorescence: suitable

technique(s)

immunofluorescence: suitable

Immunogène

Epitope: nucleoprotein
Influenza A

Application

Detect Influenza A using this Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated validated for use in IF.
Immunofluorescence

Optimal dilutions must be determined by end user.
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral

Actions biochimiques/physiologiques

Specific for the Influenza A nucleoprotein. Has stronger binding with N1-type Flu A. Has been shown to react with the H5N1 strain. No cross reactivity seen to influenza B or other respiratory viruses.

Forme physique

Biotin conjugated purified immunoglobulin. Liquid in 0.01M PBS, pH=7.1, 0.1% Sodium Azide with 15 mg/mL BSA as stabilizer.

Notes préparatoires

Maintain at 2 to 8°C for up to 12 months from date of receipt. Protect from Light.

Autres remarques

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Informations légales

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

12 - Non Combustible Liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Kai Wu et al.
ACS applied materials & interfaces, 14(8), 9945-9969 (2022-02-16)
The giant magnetoresistance (GMR) effect has seen flourishing development from theory to application in the last three decades since its discovery in 1988. Nowadays, commercial devices based on the GMR effect, such as hard-disk drives, biosensors, magnetic field sensors, microelectromechanical
Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection.
Koutsonanos, DG; Vassilieva, EV; Stavropoulou, A; Zarnitsyn, VG; Esser, ES; Taherbhai et al.
Scientific Reports null
David J Holthausen et al.
Immunity, 46(4), 587-595 (2017-04-20)
Although vaccines confer protection against influenza A viruses, antiviral treatment becomes the first line of defense during pandemics because there is insufficient time to produce vaccines. Current antiviral drugs are susceptible to drug resistance, and developing new antivirals is essential.
Mehfuz Zaman et al.
Clinical & translational immunology, 10(9), e1337-e1337 (2021-09-17)
The upper respiratory tract is the major entry site for Streptococcus pyogenes and influenza virus. Vaccine strategies that activate mucosal immunity could significantly reduce morbidity and mortality because of these pathogens. The severity of influenza is significantly greater if a
Felix Broecker et al.
NPJ vaccines, 4, 31-31 (2019-07-26)
Current seasonal influenza virus vaccines only provide limited, short-lived protection, and antigenic drift in the hemagglutinin surface glycoprotein necessitates their annual re-formulation and re-administration. To overcome these limitations, universal vaccine strategies that aim at eliciting broadly protective antibodies to conserved
Afficher tous les articles scientifiques apparentés

Questions

Reviews

No rating value

Active Filters

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique